Identification of KLK10 as a therapeutic target to reverse trastuzumab resistance in breast cancer

Trastuzumab, the first antibody widely used in anti-HER2 targeted therapy, dramatically improved the overall outcome of HER2 positive breast cancer patients. However, trastuzumab resistance emerged as a major problem in its clinical application. In order to explore mechanisms underlying trastuzumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhuo, Ruan, Beihong, Jin, Yi, Zhang, Yulong, Li, Jiaqiu, Zhu, Liyuan, Xu, Wenxia, Feng, Lifeng, Jin, Hongchuan, Wang, Xian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346730/
https://www.ncbi.nlm.nih.gov/pubmed/27825132
http://dx.doi.org/10.18632/oncotarget.13104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346730/
https://www.ncbi.nlm.nih.gov/pubmed/27825132
http://dx.doi.org/10.18632/oncotarget.13104

Ejemplares similares